Welcome to our dedicated page for Nuvalent news (Ticker: NUVL), a resource for investors and traders seeking the latest updates and insights on Nuvalent stock.
Nuvalent, Inc. develops precisely targeted small-molecule therapies for clinically proven kinase targets in cancer. Its news centers on investigational programs including zidesamtinib for ROS1-positive NSCLC, neladalkib for ALK-positive NSCLC, and HER2-altered NSCLC research, with updates on clinical data from ARROS-1 and ALKOVE-1, FDA submission activity, companion-diagnostic collaborations, and discovery-stage programs.
Company updates also cover quarterly financial results, research and development spending, cash resources, commercial-readiness activities for potential oncology launches, medical-meeting presentations, and leadership or governance developments tied to its clinical-stage biopharmaceutical model.
Nuvalent (NUVL) has outlined its 'OnTarget 2026' plan, targeting its first potential FDA approval in 2026. Key 2025 milestones include: reporting pivotal data for zidesamtinib in ROS1-positive NSCLC patients in H1 2025, submitting an NDA by mid-2025, and reporting pivotal data for neladalkib in ALK-positive NSCLC patients by year-end 2025.
The company has shown strong enrollment progress, with 430 patients enrolled in the ARROS-1 trial for zidesamtinib and 596 patients in the ALKOVE-1 trial for neladalkib as of December 31, 2024. The company plans to initiate the ALKAZAR Phase 3 trial for neladalkib in H1 2025 and continues to progress its HEROEX-1 trial for NVL-330.
Nuvalent reports having sufficient cash runway into 2028 to support clinical programs and commercial infrastructure development.
Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company developing targeted cancer therapies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. James Porter, Ph.D., the company's Chief Executive Officer, will deliver a presentation on Tuesday, January 14, 2025, at 9:00 a.m. PT in San Francisco. The presentation will be accessible via live webcast through the Investors section of Nuvalent's website and will remain available for 30 days afterward.
Nuvalent (NUVL) has appointed Grant Bogle to its Board of Directors, bringing nearly four decades of biotechnology leadership experience. Bogle's previous roles include CEO of Epizyme and Chief Commercial Officer at TESARO, both of which were successfully acquired by larger pharmaceutical companies.
The appointment comes as Nuvalent prepares for potential pivotal data readouts in 2025 from two parallel-lead programs: the ARROS-1 trial of zidesamtinib (ROS1-selective inhibitor) and the ALKOVE-1 trial of NVL-655 (ALK-selective inhibitor). The company anticipates its first pipeline approval in 2026 and plans to initiate the Phase 3 ALKAZAR trial in early 2025, comparing NVL-655 to ALECENSA for ALK-positive NSCLC treatment.
Nuvalent (NUVL), a clinical-stage biopharmaceutical company developing targeted cancer therapies, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's CEO James Porter and CFO Alexandra Balcom will engage in a fireside chat on December 3, 2024, at 3:30 p.m. ET in NYC. The presentation will be accessible via live webcast on Nuvalent's website investor section and will remain available for 30 days afterward.
Nuvalent (NUVL) reported Q3 2024 financial results and pipeline achievements. The company maintains a strong cash position of $1.2 billion, including proceeds from a $575 million public offering, extending operating runway into 2028. Key highlights include ongoing enrollment in Phase 2 trials for both ROS1 and ALK programs, with pivotal data expected in 2025. The company reported Q3 net loss of $84.3 million, with R&D expenses of $60.6 million and G&A expenses of $15.8 million. Notable appointment includes Dr. Alice Shaw to Scientific Advisory Board.
Nuvectis Pharma (NASDAQ: NVCT) showcased promising results at the AACR-NCI-EORTC Symposium, where its drug candidate NXP900 demonstrated strong synergy with ALK inhibitors in resistant non-small cell lung cancer (NSCLC) cells. The drug effectively targets SRC/YES1 kinases, addressing resistance mechanisms in cancer treatment.
The company is also anticipating data updates from NXP800's Phase 1b study in platinum-resistant, ARID1a-mutated ovarian cancer. With a current market valuation of approximately $150 million, Nuvectis is positioning itself alongside industry players like Summit Therapeutics ($15B) and Nuvalent ($6.6B) in the precision oncology space.
Nuvalent (Nasdaq: NUVL) has successfully closed its upsized public offering of Class A common stock. The biopharmaceutical company, focused on developing targeted cancer therapies, sold 5,750,000 shares at $100.00 per share, including the full exercise of the underwriters' option to purchase additional shares. The offering generated gross proceeds of approximately $575.0 million, before deducting underwriting discounts, commissions, and other expenses.
The offering was conducted through an automatically effective shelf registration statement filed with the SEC. J.P. Morgan, TD Cowen, Jefferies, and Stifel acted as joint book-running managers for the transaction. The shares were offered pursuant to a prospectus and prospectus supplement, which are available on the SEC's website and from the underwriters.
Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, has announced the pricing of an upsized public offering of 5,000,000 shares of Class A common stock at $100.00 per share. The offering is expected to generate gross proceeds of approximately $500.0 million for Nuvalent. The underwriters have a 30-day option to purchase up to an additional 750,000 shares. The offering is anticipated to close on September 18, 2024, subject to customary closing conditions. J.P. Morgan, TD Cowen, Jefferies, and Stifel are acting as joint book-running managers for the offering.
Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, has announced a $350 million public offering of Class A common stock. The company is offering all shares and plans to grant underwriters a 30-day option to purchase up to an additional 15% of shares. J.P. Morgan, TD Cowen, Jefferies, and Stifel are acting as joint book-running managers for the offering.
The offering is being made through an automatically effective shelf registration statement filed with the SEC. A preliminary prospectus supplement will be filed, detailing the terms of the offering. The completion, size, and terms of the offering are subject to market conditions and cannot be guaranteed.
Nuvalent (NUVL) presented updated Phase 1 data for its lead ROS1 and ALK inhibitors at ESMO 2024, highlighting potential best-in-class profiles. Key updates include:
1. Rapid enrollment in Phase 2 trials for both programs, with pivotal data now expected in 2025.
2. Zidesamtinib (ROS1 inhibitor) showed 44% ORR in pre-treated ROS1+ NSCLC patients, with 83% having 6+ month response duration.
3. NVL-655 (ALK inhibitor) demonstrated 38% ORR in heavily pre-treated ALK+ NSCLC patients at the recommended Phase 2 dose.
4. Both drugs were well-tolerated with favorable safety profiles.
5. A Phase 3 trial (ALKAZAR) for NVL-655 in treatment-naïve ALK+ NSCLC patients is planned for H1 2025.
These updates suggest accelerated development timelines and potential for both drugs to address unmet needs in ROS1+ and ALK+ NSCLC treatment paradigms.